Werkgroep Cardiologische centra Nederland

COMPASS (Completed)

A randomized controlled trial of rivaroxaban for the prevention of cardiovascular events in patients with coronary or peripheral artery disease
Medicine
rivaroxaban
Population
ASCVD
Phase
III
Starting year
2013
More information
ClinicalTrials.gov

Publications: COMPASS

  • Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trialEur Heart J Cardiovasc Pharmacother - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.Eur J Prev Cardiol - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Bleeding and New Cancer Diagnosis in Patients with AtherosclerosisCirculation - Abstract - COMPASS - ASCVD
  • Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.European Heart Journal - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.Gastroenterology - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled TrialGastroenterology - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Stroke Outcomes in the COMPASS TrialCirculation - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.Lancet - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.Can J Cardiol - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseN Engl J Med - Abstract - Alings, prof. dr. A.M.W. - COMPASS - ASCVD

Publications by WCN study

Publications WCN studies by WCN member